DaVita Inc. (DVA)
DVA Stock Price Chart
Key Info
| Market Cap | 12.24B |
| Revenue (ttm) | 11.54B |
| Net Income (ttm) | 844.74M |
| Shares Out | 120.91M |
| EPS (ttm) | 6.68 |
| PE Ratio | 16.36 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $109.30 |
| Previous Close | $105.42 |
| Change ($) | 3.88 |
| Change (%) | 3.68% |
| Day's Open | 106.08 |
| Day's Range | 106.00 - 109.30 |
| Day's Volume | 601,957 |
| 52-Week Range | 64.99 - 113.39 |
DVA Stock News
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Is DaVita (DVA) a great pick from the value investor's perspective right now? Read on to know more.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).
As of late, it has definitely been a great time to be an investor in DaVita (DVA).
DENVER, Nov. 23, 2020 /PRNewswire/ -- DaVita Inc. today announced its annual cycling event, Tour DaVita, raised nearly $1 million to benefit Bridge of Life, a nonprofit founded by DaVita that ...
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
Is (DVA) Outperforming Other Medical Stocks This Year?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...
SACRAMENTO, Calif., Nov. 4, 2020 /PRNewswire/ -- DaVita Kidney Care, a leading provider of kidney care services in the United States, issued the following statement: "We are grateful that Cali...
Davita Healthcare Partners sees its Relative Strength Rating move into the 80-plus level. The post Davita Healthcare Partners Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on ...
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
Rise in coronavirus cases and uncertainties revolving around the election might keep markets volatile for some time. Here are five stocks to invest in and play safe.
DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.
DaVita, Inc. (DVA) CEO Javier Rodriguez on Q3 2020 Results - Earnings Call Transcript
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 20.81% and -0.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...
DENVER, Oct. 29, 2020 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the third quarter ended September 30, 2020. During the quarter, notwithstanding the ...
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (DVA) Outperforming Other Medical Stocks This Year?
DENVER, Oct. 22, 2020 /PRNewswire/ -- DaVita Clinical Research (DCR) will present 14 research abstracts from company representatives and medical professionals at the American Society of Nephro...
Many Warren Buffett stocks remain buys.
DENVER, Oct. 15, 2020 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2020, a...
DaVita HealthCare (DVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Grab these four stocks that continue to show tremendous promise despite market volatility resulting from the coronavirus pandemic.
DaVita's business model is able to provide the company with very reliable and stable revenues, as patients need their dialysis treatment on a constant basis.
These three MedTech stocks are expected to grow post their Q3 earnings release.
These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.
This apparently simple-to-understand investing discipline has its own share of pitfalls.
With four potential Covid-19 vaccine candidates from Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), AstraZeneca PLC (NYSE:AZN) and Johnson & Johnson (NYSE:JNJ) now in late-stage human tri...
Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
DaVita (DVA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
With the market selling off hard and both economic and political uncertainty on the rise, many investors yearn to turn to the most trusted and respected investors in history.
Warren Buffett (Trades, Portfolio), head of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B), disclosed this week his firm reduced its stake in DaVita Inc.
Market sentiment is down lately due to Fed's muted outlook and rising cases of coronavirus in Europe.
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DENVER, Sept. 17, 2020 /PRNewswire/ -- DAVITA INC.
Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.
DENVER, Sept. 15, 2020 /PRNewswire/ -- DAVITA INC.
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors in the current market environment, reducing the risk of a downside.
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
DENVER, Sept. 8, 2020 /PRNewswire/ -- DaVita Inc.
The S&P 500 posted its worst single-session drop in nearly three months mainly on profit booking. While high-flying tech names were hurt the most, laggards are better positioned.
3 Top Outpatient and Home Healthcare Stocks to Watch Out For
About DVA
DaVita provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In ad... [Read more...]
| Industry Medical Care Facilities | IPO Date Oct 31, 1995 |
| CEO Javier Rodriguez | Employees 65,000 |
| Stock Exchange NYSE | Ticker Symbol DVA |
Financial Performance
In 2019, DaVita's revenue was $11.39 billion, a decrease of -0.14% compared to the previous year's $11.40 billion. Earnings were $810.98 million, an increase of 408.79%.
Analyst Forecasts
According to 12 analysts, the average rating for DaVita stock is "Hold." The 12-month stock price forecast is 102.70, which is a decrease of -6.04% from the latest price.